Arcus Biosciences, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Arcus Biosciences, Inc. (RCUS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-02-25
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $70.53M.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.00M, a 96.84% decline from fiscal 2021.
- Arcus Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $95.00M, a 1087.50% increase from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |||||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 | ||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $3.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.00M 10-Q · filed 2023-11-07 | $3.03M 10-Q · filed 2022-11-02 | ||||
| 2022-06-30 | $3.00M 10-Q · filed 2023-08-07 | $3.03M 10-Q · filed 2022-08-03 | |||||
| 2021-12-31 | $70.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $70.53M derived: sum of 2 quarters · filed 2024-02-21 | $95.00M 10-K · filed 2024-02-21 | $95.40M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $24.47M 10-Q · filed 2022-11-02 | |||||
| 2021-06-30 | $24.47M 10-Q · filed 2022-08-03 | ||||||
| 2020-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.20M derived: sum of 2 quarters · filed 2023-02-28 | $8.00M 10-K · filed 2023-02-28 | $8.02M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $13.00M 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $5.80M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |